Relay Therapeutics (RLAY) Could Be 38% Undervalued On Q3 Earnings And Pipeline Progress

Relay Therapeutics (RLAY) is back in focus after reporting third quarter 2026 results, pairing wider losses with fresh updates on its late stage cancer pipeline and commercial planning efforts.

The latest selloff tells you how conflicted the market is on Relay Therapeutics. The share price has fallen 5.71% over the past day and 12.69% across the last week, yet the year to date share price return is 107.82% and the 1 year total shareholder return is 160.34%. Momentum has cooled recently after a strong run that was built on rising expectations around its cancer and vascular anomaly programs.

Scan other high-conviction biotech ideas riding similar clinical catalysts by checking the hand-picked 34 healthcare AI stocks that could sit alongside Relay Therapeutics in a research watchlist.

Relay Therapeutics now appears to be a stronger operator with clearer late-stage plans, yet the share price has just slipped again. Are you paying up for the story or getting a sensible entry point?

Most Popular Narrative: 38% Undervalued

Relay Therapeutics closed at $17.00, while the most followed narrative anchors fair value closer to $27.58 and leans heavily on late stage cancer and vascular anomaly programs to support that gap.

Analysts expect Relay Therapeutics to turn zovegalisib into a multi-indication cancer and vascular anomalies franchise, supported by ongoing and planned Phase 3 trials and a pipeline that also includes NRAS and Fabry disease programs.

See why 3 investors see Relay Therapeutics as 38% undervalued.

Result: Fair Value of $27.58 (UNDERVALUED)

Still, the Relay Therapeutics story only holds if zovegalisib’s pivotal breast cancer and vascular anomaly trials deliver and if regulators support the proposed accelerated path.

Find out about the key risks to this Relay Therapeutics narrative.

Next Steps

Mixed signals around Relay Therapeutics can be confusing, so move quickly, review the full risk and reward stack, and form your own stance with the 3 key rewards and 2 important warning signs.

Looking for more Relay Therapeutics-sized ideas?

If you stop at Relay Therapeutics, you risk missing other opportunities that fit your style and risk profile, so put the full screener toolkit to work.

• Target reliable income streams by scanning dividend payers that combine high yields with staying power through the 6 dividend fortresses.
• Hunt for mispriced quality by filtering for companies that pair strong fundamentals with appealing valuations using the 21 high quality undiscovered gems.
• Lower portfolio stress by focusing on businesses with sturdier financial foundations through the list of solid balance sheet and fundamentals (24 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com